All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Levels of Serum Matrix Metalloprotease-12 and Tissue Inhibitor of Matrix Metalloprotease-3 in Patients with Essential Hypertension and Heart Failure with Mid- Range Ejection Fraction

Background: The aim of our study was to: (1) Determine levels of matrix metalloprotease-12 (MMP-12) and tissue inhibitor of matrix metalloprotease -12 (TIMP-3) in patients with arterial hypertension (AH) and heart failure with midrange ejection fraction (HfmrEF) and (2) to compare their levels with healthy controls. Methods: 56 patients with AH and HfmrEF were examined, mean age 65.62 ± 9.69 (Group 1); and healthy subjects for controls (n=12), mean age 56.4 ± 5.53 (Group 2). 41 of patients were with hypertensive mediated organ damage and 15 were without. ELISA was used for measuring MMP-12 and TIMP-3. Results: Serum MMP-12 levels were statistically significantly lower in patients, than in controls: 0.0033 (0.0022 ÷ 0.0071) vs. 0.0075 (0.0068 ÷ 0.016) (KW=7.37; p=0.006). MMP-12 showed correlation with treatment with ACE (r=0.48; p=0.005) and ARB (r=-0.33; p=0.05); BMI (r=0.33; p=0.05), MMP-12 and grade of AH (r=0.28; p=0.03); MMP- 12 and statin (r=-0.30; p=0.02). TIMP-3 levels in patients were lower- 5.051 (2.062 ÷ 10.463) than controls 6.460 (1.007 ÷ 12.520) (p<0.05), but not significantly. TIMP3 showed correlation with grade of AH (r=0.85; p=0.02) and PLVW (r=-0.40; p=0.03). Conclusions: Our results show correlation between serum TIMP-3, MMP-12 levels and grade of arterial hypertension in patients with HfmrEF. TIMP-3 and MMP-12 might be eventually used as markers for control of AH. We suggest that MMP- 12 and TIMP-3 are associated with development and progression of hypertensive mediated organ damage.

Author(s): Asparuh Nikolov*, Maria Tzekova, Alexander Blazhev, Konstantin Kostov, Ana Kostadinovska and Nikolay Garev

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+